1395 related articles for article (PubMed ID: 25446887)
1. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
Petkovich M; Melnick J; White J; Tabash S; Strugnell S; Bishop CW
J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
[TBL] [Abstract][Full Text] [Related]
2. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
[TBL] [Abstract][Full Text] [Related]
3. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
[TBL] [Abstract][Full Text] [Related]
4. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
Sprague SM; Silva AL; Al-Saghir F; Damle R; Tabash SP; Petkovich M; Messner EJ; White JA; Melnick JZ; Bishop CW
Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
[TBL] [Abstract][Full Text] [Related]
5. Chronic moderate ethanol intake differentially regulates vitamin D hydroxylases gene expression in kidneys and xenografted breast cancer cells in female mice.
García-Quiroz J; García-Becerra R; Lara-Sotelo G; Avila E; López S; Santos-Martínez N; Halhali A; Ordaz-Rosado D; Barrera D; Olmos-Ortiz A; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2017 Oct; 173():148-156. PubMed ID: 27639478
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Effects of Vitamin D
Batacchi Z; Robinson-Cohen C; Hoofnagle AN; Isakova T; Kestenbaum B; Martin KJ; Wolf MS; de Boer IH
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1498-1506. PubMed ID: 28768705
[TBL] [Abstract][Full Text] [Related]
8. Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults.
Vaes AMM; Tieland M; de Regt MF; Wittwer J; van Loon LJC; de Groot LCPGM
Clin Nutr; 2018 Jun; 37(3):808-814. PubMed ID: 28433267
[TBL] [Abstract][Full Text] [Related]
9. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
Sprague SM; Strugnell SA; Bishop CW
Expert Rev Endocrinol Metab; 2017 Sep; 12(5):289-301. PubMed ID: 30058895
[TBL] [Abstract][Full Text] [Related]
10. Dietary vitamin D intake is not associated with 25-hydroxyvitamin D3 or parathyroid hormone in elderly subjects, whereas the calcium-to-phosphate ratio affects parathyroid hormone.
Jungert A; Neuhäuser-Berthold M
Nutr Res; 2013 Aug; 33(8):661-7. PubMed ID: 23890356
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. The renal metabolism of 25-hydroxyvitamin D3 in the rat: regulation by 1,25-dihydroxyvitamin D3.
Turner RT; Bell NH; Baylink DJ
Calcif Tissue Int; 1983 Jul; 35(4-5):438-42. PubMed ID: 6604565
[No Abstract] [Full Text] [Related]
14. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
15. A High-Calcium and Phosphate Rescue Diet and VDR-Expressing Transgenes Normalize Serum Vitamin D Metabolite Profiles and Renal Cyp27b1 and Cyp24a1 Expression in VDR Null Mice.
Kaufmann M; Lee SM; Pike JW; Jones G
Endocrinology; 2015 Dec; 156(12):4388-97. PubMed ID: 26441239
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D Status in Chronic Kidney Disease - UVB Irradiation Is Superior to Oral Supplementation.
Krause R; Roth HJ; Kaase H; Stange R; Holick MF
Anticancer Res; 2016 Mar; 36(3):1397-401. PubMed ID: 26977042
[TBL] [Abstract][Full Text] [Related]
17. Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD.
Levin A; Tang M; Perry T; Zalunardo N; Beaulieu M; Dubland JA; Zerr K; Djurdjev O
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1447-1460. PubMed ID: 28550081
[TBL] [Abstract][Full Text] [Related]
18. Generation of 1,25-dihydroxyvitamin D
Nishikawa M; Yasuda K; Takamatsu M; Abe K; Nakagawa K; Tsugawa N; Hirota Y; Tanaka K; Yamashita S; Ikushiro S; Suda T; Okano T; Sakaki T
J Steroid Biochem Mol Biol; 2019 Jan; 185():71-79. PubMed ID: 30031146
[TBL] [Abstract][Full Text] [Related]
19. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
[TBL] [Abstract][Full Text] [Related]
20. Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD.
Stubbs JR; Zhang S; Friedman PA; Nolin TD
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1965-73. PubMed ID: 25183657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
